Haemonetics Corporation
HAENYSEHealthcare● Active
$73.36
+$2.08(+2.92%)
Market Cap$3.3B
P/E Ratio—
52W High$87.32
52W Low$47.32
Haemonetics Corporation (HAE) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · HAE · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.33B | $1.36B | $1.31B | $1.17B | $0.99B |
| Cost of Revenue | $0.59B | $0.58B | $0.60B | $0.55B | $0.46B |
| Gross Profit | $0.74B | $0.78B | $0.71B | $0.62B | $0.53B |
| Gross Margin %(computed) | 55.74% | 57.21% | 54.38% | 53.30% | 53.44% |
| Operating Expenses | |||||
| R&D Expenses | $0.06B | $0.07B | $0.06B | $0.06B | $0.06B |
| G&A Expenses | $0.00B | $0.41B | $0.41B | $0.37B | $0.33B |
| Total Operating Expenses | $0.50B | $0.56B | $0.55B | $0.47B | $0.45B |
| Operating Income | $0.24B | $0.22B | $0.16B | $0.16B | $0.08B |
| Operating Margin %(computed) | 18.10% | 16.30% | 12.60% | 13.35% | 8.13% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.03B | $0.01B | $0.01B | $0.01B | $0.02B |
| Income Before Tax | $0.13B | $0.21B | $0.15B | $0.14B | $0.06B |
| Income Tax Expense | $0.03B | $0.04B | $0.03B | $0.03B | $0.02B |
| Net Income | $0.10B | $0.17B | $0.12B | $0.12B | $0.04B |
| Net Margin %(computed) | 7.29% | 12.32% | 8.98% | 9.87% | 4.37% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $2.05 | $3.31 | $2.32 | $2.27 | $0.85 |
| Wtd Avg Shares | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B |
| EBITDA | $0.40B | $0.36B | $0.30B | $0.25B | $0.19B |
| EBITDA Margin %(computed) | 29.77% | 26.16% | 22.57% | 21.56% | 19.30% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Haemonetics Corporation data
About Haemonetics Corporation (HAE) Income Statement
Haemonetics Corporation (HAE) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2026, HAE reported revenue of $1.33B, gross profit of $0.74B (gross margin 55.74%), and net income of $0.10B — a net profit margin of 7.29%.
Frequently asked questions
HAE · 4 questionsHaemonetics Corporation (HAE) reported revenue of $1.33B for 2026, down 2.0% year-over-year.
HAE revenueHAE salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08